Crossmark

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

Crossref DOI link: https://doi.org/10.1038/bjc.2015.55

Published Online: 2015-02-17

Published Print: 2015-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Péron, J

Roy, P

Ding, K

Parulekar, W R

Roche, L

Buyse, M
License Information

Text and Data Mining valid from 2015-02-17
More Information

Article History

Received: 7 November 2014

Revised: 31 December 2014

Accepted: 12 January 2015

First Online: 17 February 2015

Competing interests

: The authors declare no conflict of interest.